See how adding Eleview® to your practice may increase your procedural efficiency at every step. From preparation to administration, clinical use through to recovery, rely on Eleview® for easy and safe GI endoscopic procedures.1

Image of ampoules for administration of Eleview® submucosal injection agent


Eleview® twist-and-go ampoules are premixed with methylene blue. This saves staff preparation time, offers consistency, and streamlines administration.

Eleview® dosing


Review the dosing guidelines for Eleview® submucosal injection agent for GI endoscopic resection procedures.

Eleview® temperature


Learn how to properly store Eleview® prior to use and how to store the unused ampoules.

Options for ordering Eleview®

Ordering Eleview®

Discover the multiple ordering options available for Eleview® submucosal injection agent via the Aries network of suppliers.


Eleview® submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device.


Patients with known sensitivity to any of the components contained in Eleview®.


  • The endoscopist injecting Eleview® must be experienced in the administration technique.
  • The safety of Eleview® has not been established in pregnant or lactating women, or in children under 18 years of age.
  • Eleview® is provided in single-use ampoules. Eleview® should not be reused after the first opening. Any emulsion not injected during the procedure should not be reused for another endoscopic procedure.
  • Do not use if the primary packaging (ampoule) or secondary packaging (aluminum pouch) is damaged.
  • Do not use if the twist-off cap is damaged.
  • Do not use if the emulsion is not clear, shows any signs of opalescence, or contains floating or precipitated visible particles.
  • The product compatibility with other substances has not been tested.


Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview®.


The administered dose of Eleview® should be determined based on the dimensions of the lesion to be removed. Inject into the submucosa the amount of Eleview® needed to form a submucosal cushion of optimal height and shape for the lesion to be removed. During the procedure do not exceed a total dose of 50 mL per patient, either in single or in multiple administrations.

Please see Instructions for Use for complete Important Safety Information.